Daniel A. Pryma 5th International Symposium on Phaeochromocytoma and Paraganglioma 2017

Abstracts this author is presenting:

• AZEDRA^® (iobenguane I 131) in patients with malignant and/or recurrent pheochromocytoma/paraganglioma (PPGL):  final results of a multi-center, open-label, pivotal phase 2b study — Symposium 7: Management I - New Horizons